ENHANCEMENT OF LUMBAR FUSION WITH GROWTH FACTORS--PRIMATE MODEL

SPID编号：31 腰椎融合术通常在人类中进行，但失败率 据报道，骨愈合的范围为5- 36%。最近，双方 重组DNA技术合成骨诱导生长因子 和牛源性骨蛋白（BP）已被证明可以诱导骨 重组人脑形态发生学 蛋白质（rhBMP-2）和BP都能有效地生成脊柱 在兔子模型中进行融合。为了确定合适的剂量， 人类使用的生长因子，并确定愈合的速度， 选择了非人灵长类动物模型。剂量高于预期， 在灵长类动物中制造骨骼所需的时间，但这两种治疗方法都是 成功未来一年的研究将集中在精确的剂量上 并探索替代载体材料， 生长因子这些研究对于提供信息至关重要 这是下一步人体临床试验所需要的。这种治疗， 如果成功，将对脊柱患者的护理产生重大影响， 防止5-35%的患者多次手术， 第一次尝试就做了脊柱融合

SPID#: 31 Lumbar spinal fusion is commonly performed in humans but the failure rate of bone union is reported to range from 5-36%. Recently, both osteoinductive growth factors synthesized by recombinant DNA technology and bovine derived bone protein (BP) have been shown to induce bone formation in heterotopic sites Recombinant human Brain Morphogenetic Protein (rhBMP-2) and BP have both been effective in generating spine fusions in a rabbit model. To determine the appropriate dose of these growth factors for human use and to determine the speed of healing, a non-human primate model has been chosen. Higher doses than expected were required to make bone in the primate, but both treatments were successful. Studies in the upcoming year will focus on the precise doses and explore alternative carrier materials that will better bind the growth factors. These studies are critical to providing the information needed for the next step which is human clinical trials. This treatment, if successful, will signifcantly impact on the care of spine patients and prevent multiple surgeries in the 5-35% of patients who do not heal their spine fusions on the first attempt.